Aug. 1, 2019: Raltegravir OK in pregnancy; HIV disclosure and viral suppression among pregnant women; newborn size following HIV exposure; causes of hearing problems among people with HIV.
Switching HIV treatment regimens during the first trimester; drivers of viral breakthrough during pregnancy; HIV’s effect on liver risk after hepatitis C treatment; hepatic steatosis among young people with HIV.
The impact of stigma on cognitive performance; risk factor dissonance among young black MSM; pregnancy and the HIV care continuum; new data on pediatric raltegravir use.
Bridgette Brawner, Ph.D., APRN, was recently honored for her research on heterosexually active black teens with mental illness -- a group that's under-represented in HIV prevention campaigns.
Kistin Nolan, M.P.H., and colleagues helped pilot a retention program designed to accommodate the emotional turmoil that makes it more difficult for young people with HIV to successfully navigate the health care system.
Despite their increased risk, only one-third of adolescents and young adults with known opioid use disorder were screened for hepatitis C, according to a study released at the IDWeek conference in San Francisco.
Efavirenz (Sustiva, Stocrin) use was associated with a 60% increased risk of neurological conditions in children, according to data presented at IDWeek 2018 in San Francisco.
HIV Prevention and Treatment Strategies for Africa's Growing Teen and Young Adults Are Central to Future World Progress
For the world's HIV epidemics to be controlled, effective community-based prevention programs reaching adolescents and young people, especially in sub-Saharan Africa, need to be developed, funded, and scaled up.
The first global comparison of adolescents who acquired HIV as newborns highlights the challenges around treatment for children in developing countries.
The risk of transmitting HIV through the breastmilk of virally suppressed women in high-income countries is not known.